The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP), Cardiovascular Events, and Mortality in Patients With Stable Coronary Heart Disease
Open accessAbstract
CONTEXT: Identification of individuals at high risk for cardiovascular events is important for the optimal use of primary and secondary prevention measures. OBJECTIVE: To determine whether plasma levels of amino terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP) predict cardiovascular events or death independent of other available prognostic tests. DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort study (2000-2002) of 987 individuals in California with stable coronary heart disease in the Heart and Soul Study, who were followed up for a mean of 3.7 (range, 0.1-5.3) years. MAIN OUTCOME MEASURES: The association of baseline NT-proBNP levels with death or cardiovascular events (myocardial infarction, stroke, or heart failure). Traditional clinical risk factors, echocardiographic measures, ischemia, other biomarkers, and New York Heart Association classification were adjusted for to determine whether NT-proBNP levels were independent of other prognostic factors. Receiver operating characteristic (ROC) curves were used to assess the incremental prognostic value of adding NT-proBNP level to these other measures. RESULTS: A total of 256 participants (26.2%) had a cardiovascular event or died. Each increasing quartile of NT-proBNP level (range of quartile 1, 8.06-73.95 pg/mL; quartile 2, 74-174.5 pg/mL; quartile 3, 175.1-459 pg/mL; quartile 4, > or =460 pg/mL) was associated with a greater risk of cardiovascular events or death, ranging from 23 of 247 (annual event rate, 2.6%) in the lowest quartile to 134 of 246 (annual event rate, 19.6%) in the highest quartile (unadjusted hazard ratio [HR] for quartile 4 vs quartile 1, 7.8; 95% confidence interval [CI], 5.0-12.1; P<.001). Each SD increase in log NT-proBNP level (1.3 pg/mL) was associated with a 2.3-fold increased rate of adverse cardiovascular outcomes (unadjusted HR, 2.3; 95% CI, 2.0-2.6; P<.001), and this association persisted after adjustment for all of the other prognostic measures (adjusted HR, 1.7; 95% CI, 1.3-2.2; P<.001). The addition of NT-proBNP level to standard clinical assessment and complete echocardiographic parameters significantly improved the area under the ROC curves for predicting subsequent adverse cardiovascular outcomes (0.80 for clinical risk factors and echocardiographic parameters plus log NT-proBNP vs 0.76 for clinical risk factors and echocardiographic parameters only; P = .006). CONCLUSIONS: Elevated levels of NT-proBNP predict cardiovascular morbidity and mortality, independent of other prognostic markers, and identify at-risk individuals even in the absence of systolic or diastolic dysfunction by echocardiography. Level of NT-proBNP may help guide risk stratification of high-risk individuals, such as those with coronary heart disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Redfield, M. M., Jacobsen, S. J., Burnett, J. C., Mahoney, D. W., Bailey, K. R., & Rodeheffer, R. J. (2003) · JAMA · doi:10.1001/jama.289.2.194 · Cited by 3,004
Committee Members, Gibbons, R. J., Balady, G. J., Timothy Bricker, J., Chaitman, B. R., Fletcher, G. F., Froelicher, V. F., Mark, D. B., McCallister, B. D., Mooss, A. N., et al. (2002) · Circulation · doi:10.1161/01.cir.0000034670.06526.15 · Cited by 2,607
Plasma Natriuretic Peptide Levels and the Risk of Cardiovascular Events and Death
Wang, T. J., Larson, M. G., Levy, D., Benjamin, E. J., Leip, E. P., Omland, T., Wolf, P. A., & Vasan, R. S. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031994 · Cited by 1,527
The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary Syndromes
de Lemos, J. A., Morrow, D. A., Bentley, J. H., Omland, T., Sabatine, M. S., McCabe, C. H., Hall, C., Cannon, C. P., & Braunwald, E. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011053 · Cited by 1,284
ACC/AHA 2002 guideline update for exercise testing: summary article
Gibbons, R. J., Balady, G. J., Timothy Bricker, J., Chaitman, B. R., Fletcher, G. F., Froelicher, V. F., Mark, D. B., McCallister, B. D., Mooss, A. N., O’Reilly, M. G., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02164-2 · Cited by 1,229
Guidelines for Exercise Testing and Prescription
Sharp, N. C. C. (1993) · British Journal of Sports Medicine · doi:10.1136/bjsm.27.2.138-a · Cited by 1,183
Tsutamoto, T., Wada, A., Maeda, K., Hisanaga, T., Maeda, Y., Fukai, D., Ohnishi, M., Sugimoto, Y., & Kinoshita, M. (1997) · Circulation · doi:10.1161/01.cir.96.2.509 · Cited by 963
Guidelines for Exercise Testing and Prescription
Scavarda, A. (1986) · Military Medicine · doi:10.1093/milmed/151.9.465a · Cited by 842
Luepker, R. V., Apple, F. S., Christenson, R. H., Crow, R. S., Fortmann, S. P., Goff, D., Goldberg, R. J., Hand, M. M., Jaffe, A. S., Julian, D. G., et al. (2003) · Circulation · doi:10.1161/01.cir.0000100560.46946.ea · Cited by 810
Depressive Symptoms and Health-Related Quality of Life: The Heart and Soul Study
Ruo, B., Rumsfeld, J. S., Hlatky, M. A., Liu, H., Browner, W. S., & Whooley, M. A. (2003) · JAMA · doi:10.1001/jama.290.2.215 · Cited by 747
Self-citation
Cited by
Daniels, L. B., & Maisel, A. S. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.021 · Cited by 952
Authors/Task Force Members, Poldermans, D., Bax, J. J., Boersma, E., De Hert, S., Eeckhout, E., Fowkes, G., Gorenek, B., Hennerici, M. G., Iung, B., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp337 · Cited by 738
Poldermans, D., Bax, J. J., Boersma, E., De Hert, S., Eeckhout, E., Fowkes, G., Gorenek, B., Hennerici, M. G., Iung, B., Kelm, M., et al. (2010) · European Journal of Anaesthesiology · doi:10.1097/eja.0b013e328334c017 · Cited by 683
Disparities in Cardiovascular Disease Risk in the United States
Graham, G. (2015) · Current Cardiology Reviews · doi:10.2174/1573403x11666141122220003 · Cited by 422
Lipshultz, S. E., Miller, T. L., Scully, R. E., Lipsitz, S. R., Rifai, N., Silverman, L. B., Colan, S. D., Neuberg, D. S., Dahlberg, S. E., Henkel, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.3404 · Cited by 323
Metadata
- Authors
- Bibbins-Domingo, K., Gupta, R., Na, B., Wu, A. H. B., Schiller, N. B., & Whooley, M. A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2007-01-10
- Volume
- 297
- Issue
- 2
- Pages
- 169
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2159377744
- Cited by
- 276
- References
- 33
- FWCI
- 25.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP), Cardiovascular Events, and Mortality in Patients With Stable Coronary Heart Disease. https://app.cochat.ai/papers/10.1001/jama.297.2.169
- The paper
- Bibbins-Domingo, K., Gupta, R., Na, B., Wu, A. H. B., Schiller, N. B., & Whooley, M. A. (2007). N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP), Cardiovascular Events, and Mortality in Patients With Stable Coronary Heart Disease. JAMA. https://doi.org/10.1001/jama.297.2.169
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.